Trends in lobular carcinoma in situ management: endocrine therapy use in California and New Jersey
暂无分享,去创建一个
[1] J. Unger,et al. How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? , 2017, npj Breast Cancer.
[2] Amy M. Sitapati,et al. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. , 2017, The Journal of the National Comprehensive Cancer Network.
[3] E. Paskett,et al. Decision making for breast cancer prevention among women at elevated risk , 2017, Breast Cancer Research.
[4] S. Pruthi,et al. Physician and Patient Barriers to Breast Cancer Preventive Therapy , 2016, Current Breast Cancer Reports.
[5] S. Shahbazi,et al. Influence of physician, patient, and health care system characteristics on the use of outpatient mastectomy. , 2016, American journal of surgery.
[6] J. Wardle,et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] H. Witteman,et al. What Matters to Women When Making Decisions About Breast Cancer Chemoprevention? , 2016, The Patient - Patient-Centered Outcomes Research.
[8] A. Jemal,et al. Cancer statistics: Breast cancer in situ , 2015, CA: a cancer journal for clinicians.
[9] I. Ahmed,et al. UK national survey of management of breast lobular carcinoma in situ. , 2015, Annals of the Royal College of Surgeons of England.
[10] Kadakia Kc,et al. Adjuvant endocrine therapy in premenopausal women with breast cancer , 2015 .
[11] Y. Takeuchi,et al. Safety of 3-year raloxifene treatment in Japanese postmenopausal women aged 75 years or older with osteoporosis: a postmarketing surveillance study , 2015, Menopause.
[12] J. Reis-Filho,et al. Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Chávez-MacGregor,et al. Barriers to the Use of Breast Cancer Risk Reduction Therapies. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[14] A. Akincigil,et al. Validation of the Spanish Version of the Mammography-Specific Self-Efficacy Scale. , 2015, Oncology nursing forum.
[15] R. Shi,et al. Effects of payer status on breast cancer survival: a retrospective study , 2015, BMC Cancer.
[16] A. Maxwell,et al. Outcomes of patients with lobular in situ neoplasia of the breast: the role of vacuum-assisted biopsy. , 2014, Breast.
[17] D. Winchester,et al. Changing surgical trends in young patients with early stage breast cancer, 2003 to 2010: a report from the National Cancer Data Base. , 2014, Journal of the American College of Surgeons.
[18] S. Narod,et al. Tamoxifen for women at high risk of breast cancer , 2014, Breast cancer.
[19] Pamela R. Portschy,et al. Trends in Incidence and Management of Lobular Carcinoma In Situ: A Population-Based Analysis , 2013, Annals of Surgical Oncology.
[20] C. Ingram,et al. The role of vacuum assisted biopsy (VAB) in the diagnostic breast pathway , 2013 .
[21] Erika A. Waters,et al. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010 , 2012, Breast Cancer Research and Treatment.
[22] D. Farkas,et al. Effect of insurance status on the stage of breast and colorectal cancers in a safety-net hospital. , 2012, Journal of oncology practice.
[23] Dawn L Hershman,et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] A. González Martín,et al. Adjuvant endocrine therapy in premenopausal women with breast cancer , 2010, Breast Cancer Research and Treatment.
[25] E. Messalli,et al. Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update , 2009, International journal of women's health.
[26] M. Morrow,et al. Patient satisfaction with treatment of breast cancer: does surgeon specialization matter? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] L. Ford,et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.
[28] R. Severson,et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] K. Helzlsouer,et al. Breast carcinoma chemoprevention in the community setting , 2005, Cancer.
[30] J. Begun,et al. Diffusion of breast conserving surgery in medical communities. , 2005, Social science & medicine.
[31] M. Regan,et al. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] L. Dubay,et al. Access to Care and Use of Health Services by Low-Income Women , 2001, Health care financing review.
[33] M. Nair,et al. Transforming growth factor beta related to extent of tumor angiogenesis but not apoptosis or proliferation in breast carcinoma , 1999, Breast cancer.
[34] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[35] S. Vernon,et al. The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial. , 1998, Preventive medicine.
[36] R. Frankowski,et al. Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment , 1995, Cancer.